Identify stocks that meet your criteria using seven unique stock screeners. All rights reserved. how to buy MNKD stock MannKind's stock was trading at $4.37 on January 1st, 2022. The financial health and growth prospects of MNKD . Trending now. Systematic retrieval of data or other content from StockInvest.us, whether to create or compile, post to other websites, directly or indirectly, as text, video or audio, a collection, compilation, database or directory, is prohibited absent our express prior written consent. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. Our recommended stop-loss: MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. Management has expressed confidence that the issue raised by the FDA can be resolved quickly. Real-time analyst ratings, insider transactions, earnings data, and more. MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks. The stock market shifted into rally mode in the afternoon, however, which brought the S&P 500 above the 3,800 level. The MannKind Corporation stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. MNKD Valuation Summary. Learn about financial terms, types of investments, trading strategies, and more. Q2 of 2021 was Google's third straight quarter of profitability. There is a buy signal from a pivot bottom found 27 days ago. Move Over Lithium 220 Pounds of Graphite In Every EV Battery (Ad), New "Vertical" Technology Solves Solar Power's Major Flaw (Ad). Therefore, AI Pickup would say that MannKind (MNKD) stock is overvalued. * >>>. Twitter StockInvest.us is a research service that provides financial data and technical analysis of publicly traded stocks. The MannKind Corporation stock price gained 2.83% on the last trading day (Monday, 7th Nov 2022), rising from $3.53 to $3.63. (-3.28%) Want to see which stocks are moving? Collect enough gold quick enough to perform sound . Rule Breakers. Learn about the media coverage comparison. MNKD stock is notorious for draining investment accounts. Also, from a company-specific perspective, Amazon's. One share of MNKD stock can currently be purchased for approximately $3.63. The Motley Fool recommends Johnson & Johnson. Want to see which stocks are moving? MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. 13.06%. View real-time stock prices and stock quotes for a full financial overview. All users should speak with their financial advisor before buying or selling any securities. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. That means that penny stocks, which are riskier by nature, are finding their ratings declining in the current environment. Firstly, there has been a visible shift from growth names to value stocks and Amazon ticks the wrong boxes. Mostly positive signals in the chart today. Valuation metrics show that MannKind Corporation may be overvalued. MannKind trades on the NASDAQ under the ticker symbol "MNKD.". Inflation Inflation means that the value of cash today. Real-time trade and investing ideas on Mannkind Corp MNKD from the largest community of traders and investors. Longer term, however, things look better. For instance, the Vanguard Growth Index Fund ETF (NYSE: VUG), which tracks growth stocks, is down over 26% this year to about $238. Get short term trading ideas from the MarketBeat Idea Engine. So, it should, NasdaqGM - NasdaqGM Real Time Price. Export data to Excel for your own analysis. Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Analysts who follow MannKind Corporation on average expect it to increase 102.75% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. StockTwits Get daily stock ideas from top-performing Wall Street analysts. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. 109%. MannKind Co. (NASDAQ:MNKD) issued its earnings results on Tuesday, November, 9th. 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. Since the release on April 16th, 2022, Netflix decreased all the way from 348.61 dollars to 198.4 dollars. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. When Can We Expect A Profit From MannKind Corporation (NASDAQ:MNKD)? A few months ago penny stocks with buy ratings that were doing well suddenly found themselves downgraded to a hold rating or worse. Knowing PMAEA for MNKD three weeks before Earnings Announcement can provide unique advantages in trading Earnings. SHARE THIS POST Stock Advisor. There are a lot of reasons share prices are falling. Volume fell on the last day by -3 million shares and in total, 4 million shares were bought and sold for approximately $14.99 million. MNKD | Complete MannKind Corp. stock news by MarketWatch. This suggests a possible upside of 65.3% from the stock's current price. Return. 3 Old School Automakers Making Big EV Strides, Despite Financials, Twiliio is One To Watch, 3 Reasons Another Shoe May Drop for Skechers. *Average returns of all recommendations since inception. A high-level overview of MannKind Corporation (MNKD) stock. Adam Aron selling has driven AMC stock down Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken. How can I listen to MannKind's earnings call? MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Our Flagship Service. The S&P 500 climbed by 16 percent in 2020 and nearly 27 percent in 2021. Its hard to quantify much like the tingles you feel from watching a hypnotic ASMR video is difficult to quantify. Tyvaso DPI is a potential treatment for pulmonary arterial hypertension (PAH), a condition where high blood pressure constricts or blocks blood vessels in the lungs. StockTwits Their MNKD share price forecasts range from $6.00 to $6.00. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds. Returns as of 11/07/2022. Facebook 16th is going $3.50 (14.38%) Rank: . This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. The stock now trades at levels from mid-August -- not that long ago. Google's search engine has 87% of online search market share. Receive a free world-class investing education from MarketBeat. Even though MannKind Corporation's (NASDAQ:MNKD) stock is down 14% this week, insiders who bought lately made a US$64k profit - Nasdaq, Even though MannKind Corporation's (NASDAQ:MNKD) stock is down 14% this week, insiders who bought lately made a US$64k profit, MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference - StreetInsider.com, MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswire, MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference - MannKind (NASD - Benzinga, MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference, 7 Penny Stocks with Buy Ratings to Keep Your Eye On - InvestorPlace, Interesting MNKD Call Options For October 28th, A number of insiders bought MannKind Corporation (NASDAQ:MNKD) stock last year, which is great news for shareholders - Yahoo Finance, A number of insiders bought MannKind Corporation (NASDAQ:MNKD) stock last year, which is great news for shareholders, MNKD stock gains on Phase 1 data for lung disease candidate (NASDAQ:MNKD) - Seeking Alpha, Mannkind to further advance lung disease candidate after positive Phase 1 data, MannKind Shares Fall After Completing Initial Stage Lung Disease Study, Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine - GlobeNewswire, Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine, Mannkind Corporation Stock: Ready For Your Biotech Portfolio (NASDAQ:MNKD) - Seeking Alpha, MannKind Corporation to Participate in the H.C. Wainwright - GlobeNewswire, MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, MNKD.OQ - MannKind Corporation | Stock Price & Latest News | Reuters, $9.3 Billion Worldwide Rapid Acting Insulin Industry to 2027 - Featuring Adocia, Biocon Limited and Geropharm Among Others - Yahoo Finance, Analysts Are Betting On MannKind Corporation (NASDAQ:MNKD) With A Big Upgrade This Week, Zealand Pharma Announces Financial Results for the First Half of 2022 - GlobeNewswire, Despite Lacking Profits AVEO Pharmaceuticals (NASDAQ:AVEO) Seems To Be On Top Of Its Debt - Nasdaq, Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80 - Nasdaq, Some Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Just Made A Major Cut To Next Year's Estimates - Nasdaq, Heron Therapeutics (NASDAQ:HRTX) Is Making Moderate Use Of Debt - Nasdaq, MannKind Corporation (MNKD) Q2 2022 Earnings Call Transcript - The Motley Fool, MannKind Corporation (MNKD) Q2 2022 Earnings Call Transcript, MannKind's (NASDAQ:MNKD) investors will be pleased with their stellar 268% return over the last three years, MannKind Corporation Reports 2022 Second Quarter Financial Results - Yahoo Finance, Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates, Mednax (MD) Q2 Earnings Match Estimates - Nasdaq, Cramer's lightning round: Canoo is not a buy - CNBC, United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up - Nasdaq, MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022 - GlobeNewswire, MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022, MannKind Corporation to Participate in the BTIG Biotechnology Conference - GlobeNewswire, Why Shares of MannKind Corporation Climbed 10.4% on Monday, 4 Penny Stocks To Watch After OTRK Stock Explodes Over 140% - StreetInsider.com, Why Shares of MannKind Corporation Climbed 10.4% on Monday - The Motley Fool. Sign in to your free account to enjoy all that MarketBeat has to offer. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies. The consensus among Wall Street analysts is that investors should "buy" MNKD shares. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. The Smart Score is a quantitative, data-driven rating system and does not include human . Log In. MannKind does not currently pay a dividend. NASDAQ 0.00%. Current score: Financial Juice MannKind (NASDAQ:MNKD) has a market capitalization of $916.81 million and generates $75.44 million in revenue each year. That makes the delay especially impactful. MNKD's price/sales ratio is 12; this is 531.58% higher than that of the median Healthcare stock. ET, MannKind Corporation (MNKD) Q2 2022 Earnings Call Transcript, Why Shares of MannKind Corporation Climbed 10.4% on Monday, MannKind Corporation (MNKD) Q1 2022 Earnings Call Transcript, MannKind Corporation (MNKD) Q4 2021 Earnings Call Transcript, MannKind Corporation (MNKD) Q2 2021 Earnings Call Transcript, Cumulative Growth of a $10,000 Investment in Stock Advisor, Once-in-a-Decade Buying Opportunity: 2 Trillion-Dollar Growth Stocks Near a 52-Week Low, 2 FAANG Stocks to Buy Hand Over Fist and 1 to Avoid Like the Plague, The Unfortunate Truth About Maxing Out Your 401(k), 2 Stocks Warren Buffett Is Still Buying Hand Over Fist, Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Copyright, Trademark and Patent Information. MNKD earnings call for the period ending June 30, 2021. Move Over Lithium 220 Pounds of Graphite In Every EV Battery (Ad), New "Vertical" Technology Solves Solar Power's Major Flaw (Ad). The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. Any other use, including for any commercial purposes, is strictly prohibited without our express prior written consent. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. I was about 50/50 red days and green days. The official website for the company is www.mannkindcorp.com. Facebook S&P Return. MNKD earnings call for the period ending June 30, 2021. Learn More. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Looking for new stock ideas? You would think there would be stability after decades of trying to get it right. Investing Basics . People cant decide where your mystery break take you? Will MannKind stock price go up? if you're new to investing. technical signals. MannKind - MNKD News Today $3.48 -0.09 (-2.52%) (As of 09/19/2022 05:34 PM ET) Compare Today's Range $3.37 $3.55 50-Day Range $3.33 $4.35 52-Week Range $2.49 $5.44 Volume 5.25 million shs Average Volume 4.37 million shs Market Capitalization $878.93 million P/E Ratio N/A Dividend Yield N/A Price Target $6.00 Profile Analyst Ratings Chart Over the past 222 months, MNKD's price/earnings ratio has gone down 2.5. On corrections down, there will be some support from the lines at $3.48 and $3.24. Log In Help Join The Motley . Whether youre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Returns as of 11/08/2022. That said, time is money. MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. If MannKind Corporation takes out the full calculated possible swing range there will be an estimated 10.37% move between the lowest and the highest trading price during the day. Because of AMD's growth in revenue, profit and stock price, many of the investors holding AMD stock are growth-style investors. MannKind has received no research coverage in the past 90 days. #2. Stocks are. The price has risen in 7 of the last 10 days and is up by 12.04% over the past 2 weeks. See what's happening in the market right now with MarketBeat's real-time news feed. A reason why a stock will go up. than the resistance at $3.88 (6.89%), AMC stock is down to a variety of reasons, but this economic fear is everywhere and is affecting the entire market, including the century old movie theatre chain. Mannkind Corp 3.53 0.09 (2.62%) Watch. View our full suite of financial calendars and market data tables, all for free. To that end, MannKind CEO Michael Castagna said it is stockpiling inventory in anticipation of the eventual green light. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Diaphragm muscle strength with an american band. Financial Juice Lets start with the pros of penny sleeper stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The S&P 500 and the Nasdaq Composite are off more than 1.7% . danbury, conn. and westlake village, calif., sept. 21, 2022 (globe newswire) -- mannkind corporation (nasdaq: mnkd), a company focused on the development and commercialization of innovative. Price as of November 7, 2022, 4:00 p.m. I would make 250 dollars then lose 150 dollars. Only 2.30% of the stock of MannKind is held by insiders. Earnings for MannKind are expected to grow in the coming year, from ($0.38) to ($0.13) per share. No significant news for MNKD in the past two years. Out of 1 analyst , 0 ( 0% ) are recommending MNKD as a Strong Buy, 1 ( 100% ) are recommending MNKD as a Buy, 0 ( 0% ) are recommending MNKD as a Hold, 0 ( 0% ) are recommending MNKD as a Sell, and 0 ( 0% ) are recommending MNKD as a Strong Sell. Why is Amazon stock going down? MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Stock market data coverage from CNN. View which stocks are hot on social media with MarketBeat's trending stocks report. Click to get the best stock tips daily for free! By creating a free account, you agree to our, Generational Lack in Finances Leaves Inadequate Preparedness for Life, Bulls Vs Bears: Mullen Automotive Short Interest Grows, World markets mixed ahead of US elections, inflation data, Walgreens push into comprehensive care picks up momentum, Wall Street climbs ahead of Election Day, inflation data, Stocks edge mostly higher ahead of midterm elections in US, Tyson Foods heir and CFO charged with public intoxication. The predicted opening price is based on yesterday's movements between high, low, and closing price. Trailing 12-Months. Should I buy or sell MannKind stock right now? StockInvest.us provides daily technical stock analysis commentaries and dynamically calculated RSI max/min levels. View MNKD analyst ratings or view top-rated stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. How were MannKind's earnings last quarter? 46.83% of the stock of MannKind is held by institutions. 178%. The consensus among . Stock Advisor list price is $199 per year. The biopharmaceutical company earned $22.21 million during the quarter, compared to analysts' expectations of $20.54 million. Get daily stock ideas from top-performing Wall Street analysts. So if inflation is at 1.5%, you need to get 4.5% nominal return on your bonds to achieve this goal. liable for your own investment decisions and agree to the High institutional ownership can be a signal of strong market trust in this company. 16th is going $3.08 (0.65%) 5 months ago genjuro007.267945 predicted that MNKD for May. Terms of Use and Privacy Policy. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. This stock has average movements during the day and with good trading volume, the risk is considered to be medium. The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022. MNKD stock is under heavy trading as a result of today's news. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Making the world smarter, happier, and richer. Our daily ratings and market update email newsletter. View . A buy signal was issued from a pivot bottom point on Thursday, September 29, 2022, and so far it has risen 21.40%. MannKind Corporation finds support from accumulated volume at $3.57 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Instead, it was the inspection at a third-party facility that proved to be the fly in the ointment. During the last trading day the stock fluctuated 6.41% from a day low at $3.51 to a day high of $3.74. Currency in USD, Trade prices are not sourced from all markets. 1 Wall Street analyst covering (NASDAQ: MNKD) stock is to Buy MNKD stock. Nominal interest rates are broken up into 2 components: Interest Rates (expected investor return) Expected inflation. A breakdown below any of these levels will issue sell signals. Losses were -$80.93 million, 41.4% more than in 2020. My 3k was down to about 2,800 after a week. ManKind (MNKD) shares are down after being downgraded to 'hold' by analysts at MLV & Co. Please log in to your account or sign up in order to add this asset to your watchlist. MannKind will be holding an earnings conference call on Tuesday, November 8th at 9:00 AM Eastern. Given the current short-term trend, the stock is expected to fall -20.40% during the next 3 months and, with a 90% probability hold a price between $2.07 and $2.89 at the end of this 3-month period. S&P Return. View US markets, world markets, after hours trading, quotes, and other important stock market activity. For the last week, the stock has had daily average volatility of 5.45%. That indicates that the already risky world of penny stocks is becoming riskier still. For the upcoming trading day on Tuesday, 8th we expect MannKind Corporation to open at $3.63, and during the day (based on 14 day Average True Range), 333%. In 2021, MannKind's revenue was $75.44 million, an increase of 15.81% compared to the previous year's $65.14 million. MannKind's stock is owned by a variety of institutional and retail investors. During the last day, the stock moved $0.225 between high and low, or 6.41%. Most stock quote data provided by BATS. It's a rare disease with an occurrence rate that Johnson & Johnson estimates between 50 and 100 people per million. View our MNKD earnings forecast. That average rating earns the stock an Analyst Ranking of 58, which means it ranks higher than 58 of stocks, based on data compiled by InvestorsObserver. Volume fell during the last trading day despite gaining prices. Robinhood scrambled to meet the clearinghouse collateral requirements drawing down "at least several hundred million dollars" from its bank credit lines and raising over $1 billion from its. Looking for new stock ideas? MannKind does not have a long track record of dividend growth. Not an offer or recommendation by Stocktwits. MannKind Corporation (NASDAQ: MNKD) stock surged over 26.3% on October 10th, 2017 (As of 12:39PM EDT; Source: Google finance) as analysts from H.C. Wainwright issued. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. InvestorsObserver's proprietary ranking system, gives MNKD stock a score of 34 out of a possible 100. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Think about it this way - imagine you're GIC and you need to achieve a 3% inflation adjusted return. The higher interest rates go, the more risk-averse the markets become. A. Stockinvest.us provides daily technical stock analysis commentaries and financial data for more than 25 000 publicly traded companies based on our calculated technical signals. Two primary reasons the markets will always have cycles of boom and bust are political manipulation of monetary liquidity and fear and greed. Nothing nefarious about that. (This stock has medium daily movements and this gives medium risk. Is Clothier V.F. The U.S. Dollar Index fell 1.8% on Friday and was down another 0.7% to 110.16 today. The company has a license and collaboration agreement with United Therapeutics Corporation. JS predicted that MNKD for May. Perhaps that's because there is still a clear path to approval. That means that penny stocks, which are riskier by nature, are finding their ratings declining in the current environment. The recent quarterly report sent investors to the exits. which gives a possible trading interval of +/-$0.188 (+/-5.19%) up or down from last closing price. What is MannKind's stock price forecast for 2023? 3 brokerages have issued twelve-month price targets for MannKind's shares. Learn more about MarketBeat. You may use StockInvest.us and the contents contained in StockInvest.us solely for your own individual non-commercial and informational purposes only. MannKind Corporation (NASDAQ: MNKD) If you've been following CNA Finance or my writing elsewhere, you know that one of my favorite stocks to follow in biotech is MannKind. Palantir Falls Into The Hands Of Value Investors, The Analysts Cant Keep Up with Arista Networks Stock, 3 Reasons Amazon Will Deliver Better 2023 Returns, A Turnaround is Brewing in Starbucks Stock, 7 Small-Cap Stocks That Could Rocket Higher in 2023, 7 Cash Rich Stocks That Offer Safety in Any Market, 7 Streaming Stocks that Will Stand up to Streaming Fatigue, 7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed, 7 Railroad Stocks to Keep Your Portfolio Chugging Along, 7 Solar Stocks Leading the Clean Energy Boom, 7 Water Stocks to Buy as the World Dries Up, 7 Sports Betting Stocks to Buy for Their Long-Term Possibilities, 7 Stocks to Buy to Outrun Rising Interest Rates, 7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time, MNKD.O - MannKind Corp | Stock Price & Latest News | Reuters, MannKind (MNKD) to Release Quarterly Earnings on Tuesday, MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022, 7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up - InvestorPlace. Further rise is indicated until a new top pivot has been found. Get short term trading ideas from the MarketBeat Idea Engine. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Obviously, selling some stock makes sense. Invest better with The Motley Fool. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. to move between $3.44 and $3.82, Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross. Compare Top Brokerages Here. Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. Liquidity Crisis : Because of IL&FS problem, it is going difficult for the Non-Banking Financial Companies (NBFCs) to raise the money. The MannKind stock price forecast for 2023 Jun. Whether youre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 3.318 MannKind Stock (NASDAQ: MNKD) stock price, news, charts, stock research, profile. Its Value Score of F indicates it would be a bad pick for value investors. And at that point, we will see stock prices recover surprisingly quickly. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. To make the world smarter, happier, and richer. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-0.35 Market Cap $908.40 M Shares Outstanding 257.34 M Public Float 250.09 M Yield MNKD is. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 All rights reserved. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Support, Risk & Stop-loss On the downside, the stock finds support just below today's level from accumulated volume at $3.21 and $3.18. Dive deeper with interactive charts and top stories of MANNKIND CORPORATION. Shares of MannKind (MNKD 2.83%), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (UTHR 0.80%).